Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Teva
Mallinckrodt
UBS
Merck
Fuji
McKinsey
Federal Trade Commission
Citi
McKesson

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,450,372

« Back to Dashboard

Which drugs does patent 8,450,372 protect, and when does it expire?


Patent 8,450,372 protects ZOLINZA and is included in one NDA.

This patent has forty-two patent family members in twenty-four countries.

Summary for Patent: 8,450,372

Title:Formulations of suberoylanilide hydroxamic acid and methods for producing same
Abstract: The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which comprises suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The present invention provides a process of producing said crystalline composition or pharmaceutical composition. The present invention also provides compositions with a specific particle size distribution.
Inventor(s): Wong; Jeannie Chow (Chicago, IL), Cote; Aaron S. (West Windsor, NJ), Dienemann; Erik A. (Metuchen, NJ), Gallagher; Kimberly (Green Lane, PA), Ikeda; Craig (Harleysville, PA), Moser; Justin (Collegeville, PA), Rajniak; Pavol (Lansdale, PA), Reed; Robert A. (Line Lexington, PA), Starbuck; Cindy (Branchburg, NJ), Tung; Hsien-Hsin (Edison, NJ), Wang; Qingxi (Ambler, PA), Cohen; Benjamin Max (Cranford, NJ), Capodanno; Vincent R. (Hillsborough, NJ), Sell; Brian (Royersford, PA), Miller; Thomas A. (Wakefield, MA)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:12/686,843
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
MerckZOLINZAvorinostatCAPSULE;ORAL021991-001Oct 6, 2006RXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,450,372

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,093,295Formulations of suberoylanilide hydroxamic acid and methods for producing the same► Subscribe
8,288,440Formulations of suberoylanilide hydroxamic acid and methods for producing same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,450,372

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
BrazilPI0605893► Subscribe
Canada2580367► Subscribe
China101080223► Subscribe
Costa Rica8912► Subscribe
Dominican RepublicP2006000113► Subscribe
EcuadorSP077263► Subscribe
European Patent Office2229941► Subscribe
European Patent Office2292221► Subscribe
Israel181070► Subscribe
Morocco28804► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
McKinsey
Moodys
Covington
Fuji
Fish and Richardson
Colorcon
Baxter
Daiichi Sankyo
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot